Digihost Announces Record Results for the First Quarter of 2021

TORONTO, May 19, 2021 (GLOBE NEWSWIRE) — Digihost Technology Inc. (“Digihost” or the “Company”) (TSXV: DGHI; OTCQB: HSSHF) announces its financial results as of and for the three months ended March 31, 2021 (all amounts in U.S. dollars, unless otherwise indicated). The Company’s unaudited consolidated financial statements and management’s discussion and analysis (“MD&A”) for periods ended March 31, 2021 and 2020 have been filed and made accessible under the Company’s continuous disclosure profile on SEDAR at www.sedar.com.

Michel Amar, CEO of Digihost, stated: “We are extremely pleased by the record financial results achieved by Digihost for the first quarter of 2021, reporting $5,910,974 of total comprehensive income for the period, an increase of 872% over the same period of last year. We are looking forward to building on these results through our commitment to expand our business in an environmentally and socially responsible way, thereby creating the momentum to continue our success during the remainder of 2021 and beyond.”


First Quarter 2021 Financial Highlights

The following information compares the financial results of the Company for the three months ended March 31, 2021 (“2021”) and the three months ended March 31, 2020 (“2020”):

  • Record high total comprehensive income of $5.9 million reported in 2021, compared to a total comprehensive loss of $0.76 million in 2020, an increase of 872%;
  • Revenue from digital currency mining increased by 469% to $4.8 million in 2021 compared to $0.8 million in 2020;
  • Gross profit margin increased to 44% in 2021 compared to a gross loss margin of 13% in 2020, an increase in gross margin of 57%;
  • The weighted average shares outstanding in 2021 were 44,313,754 compared to 20,257,016 in 2020.

The following information compares the financial position of the Company as at March 31, 2021 (“2021”) and as at December 31, 2020 (“2020”):

  • Cash balance of $13.19 million in 2021 compared to $0.03 million in 2020, an increase of $13.16 million;
  • Digital currencies balance of $15.16 million in 2021, comprised of 260 Bitcoins, compared to $4.51 million in 2020, comprised of 154 Bitcoins, an increase of $10.65 million and 106 Bitcoins;
  • Total assets of $43.54 million in 2021 compared to $16.52 million in 2020, an increase of $27.02 million;
  • Total liabilities of $4.40 million in 2021 compared to $6.08 million in 2020, a decrease of $1.68 million; and
  • Total shareholders’ equity of $39.14 million in 2021 compared to $10.44 million in 2020, an increase of $28.70 million.


Recent Highlights

  • On April 13, 2021, the Company announced the closing of a private placement of shares and warrants for gross proceeds of CA$25 million;
  • On April 14, 2021, the Company appointed international audit firm, Raymond Chabot Grant Thornton LLP;
  • On May 10, 2021, the Company announced the status of its Nasdaq listing application and diversification of cryptocurrency business model to include Ethereum technology;
  • On May 14, 2021, the Company announced the acquisition of 9,900 Bitcoin Miners to increase its hashrate by 925PH, and hosting agreement with Northern Data AG;
  • On May 17, 2021, the Company reported on green energy consumption, stating that 90% of the energy consumed by Digihost in its Bitcoin mining operations is from sources that create zero carbon emissions and more than 50% of the energy consumed by the Company is generated from renewable sources; and
  • The Company’s current cryptocurrency holdings are comprised of: 564 Ethereum and 299 Bitcoin.

Michel Amar commented: “Our long-term vision and business strategy is to expand our operations and evolve as a leader in the blockchain technology sector. While cryptocurrency mining is one application of blockchain technology, the blockchain sector as a whole is a monumental leap forward in information transparency, security, and decentralization. We are committed to pursue every opportunity in this sector that allows us to create significant shareholder value in an environmentally conscious manner, with the goal of eventually eliminating the Company’s already very low carbon footprint.”

(U.S.$ except per share data) Three Months Ended March 31

For the periods ended as indicated
2021

  2020

 
Revenue from digital currency mining 4,767,075   838,310  
Operating and maintenance costs (1,549,144 ) (586,336 )
Depreciation (1,109,796 ) (363,290 )
Gross profit (loss) 2,108,135   (111,316 )
General and administrative and other expenses (1,879,866 ) (579,069 )
Change in fair value of warrant liability   40,436  
Gain on disposition of cryptocurrencies   28,590  
     
Operating profit (loss) 228,269   (621,359 )
Net financial expenses (155,312 ) (7,451 )
Net income (loss) for the period 72,957   (628,810 )
     
Other comprehensive income    
Foreign currency translation adjustment 1,456    
Revaluation of digital currency 5,836,561   (137,014 )
Total comprehensive income (loss) 5,910,974   (765,824 )
Basic and diluted loss per share – diluted

Weighted average number of subordinate voting shares outstanding – basic and diluted

(0.00

44,313,754

)

(0.03

20,257,016

)

About Digihost Technology Inc.

Digihost Technology Inc. is a growth-oriented blockchain technology company primarily focused on Bitcoin mining. The Company’s mining facilities are located in Upstate New York, and are equipped with 78.7 MW of low-cost power with the option to expand to 102MW. The Company is currently hashing at a rate of 200PH with potential to expand to a rate of 3EH upon the completion of the previously announced acquisition of a 60MW power plant.

For further information, please contact:

Digihost Technology Inc.
www.digihost.ca
Michel Amar, Chief Executive Officer
T: 1-818-280-9758
Email: [email protected]

Cautionary Statement

Trading in the securities of the Company should be considered highly speculative. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

Except for the statements of historical fact, this news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) that is based on expectations, estimates and projections as at the date of this news release. Forward-looking information in this news release includes information about listing on Nasdaq, hashrate expansion, diversification of operations to include Ethereum technology, potential further improvements to profitability and efficiency across mining operations, potential for the Company’s long-term growth, and the business goals and objectives of the Company. Factors that could cause actual results, performance or achievements to differ materially from those described in such forward-looking information include, but are not limited to: risks relating to completion of the Nasdaq listing process, continued effects of the COVID19 pandemic may have a material adverse effect on the Company’s performance as supply chains are disrupted and prevent the Company from operating its assets; a decrease in cryptocurrency pricing, volume of transaction activity or generally, the profitability of cryptocurrency mining; further improvements to profitability and efficiency may not be realized; the digital currency market; the Company’s ability to successfully mine digital currency on the cloud; the Company may not be able to profitably liquidate its current digital currency inventory, or at all; a decline in digital currency prices may have a significant negative impact on the Company’s operations; the volatility of digital currency prices; and other related risks as more fully set out in the Annual Information Form of the Company and other documents disclosed under the Company’s filings at www.sedar.com. The forward-looking information in this news release reflects the current expectations, assumptions and/or beliefs of the Company based on information currently available to the Company. In connection with the forward-looking information contained in this news release, the Company has made assumptions about: the current profitability in mining cryptocurrency (including pricing and volume of current transaction activity); profitable use of the Company’s assets going forward; the Company’s ability to profitably liquidate its digital currency inventory as required; historical prices of digital currencies and the ability of the Company to mine digital currencies on the cloud will be consistent with historical prices; and there will be no regulation or law that will prevent the Company from operating its business. The Company has also assumed that no significant events occur outside of the Company’s normal course of business. Although the Company believes that the assumptions inherent in the forward-looking information are reasonable, forward-looking information is not a guarantee of future performance and accordingly undue reliance should not be put on such information due to the inherent uncertainty therein.



Retailers Increasingly Turn to FourKites to Drive End-to-End Supply Chain Visibility

Leading global retailers, including Ace Hardware, PetSmart, Walmart Canada, Dollar Tree, Michaels and Meijer choose FourKites to improve OTIF and reduce dwell time

CHICAGO, May 19, 2021 (GLOBE NEWSWIRE) — FourKites®, the #1 real-time supply chain visibility platform, today announced that its momentum in the retail sector continues to accelerate, as evidenced by unprecedented growth in new customers, total shipments tracked, miles travelled, carriers onboarded and geographies covered, amongst other key metrics. Critically, FourKites’ retail customers increased on-time, in-full (OTIF) deliveries by 38% and reduced dwell time by 14% between October 2020 to March 2021, compared to the six months prior.

Over the last six months, FourKites’ retail customer base grew by 20%; tracked shipments increased 77% in North America, 52% in Europe and 158% in Asia Pacific; and carrier onboarding rose 30% to a total carrier count of nearly 600. Moreover, total miles travelled by FourKites retail customers were up 117%, to just under 2 billion miles. Notably, during a period in which consumer behavior has demonstrably shifted to ecommerce, FourKites saw a 67% growth in LTL shipments and 152% growth in parcel shipments over the last six months.

FourKites was recently recognized in the 2021 Gartner Magic Quadrant for Real-Time Transportation Visibility Platforms for its ability to execute and with the furthest completeness of vision out of 14 companies evaluated. Gartner also recognized FourKites for its particular expertise in the Retail industry.

As shipping volumes increase and more retailers leverage the platform, FourKites continues to exercise its vision and deliver industry-first innovations specifically designed for, and often in collaboration with, its retail customers. Recent new capabilities and enhancements include:

  • FourKites Retail Manager and Merchandiser Apps provide users with real-time shipment tracking and predicted ETAs via their mobile devices so they can spend more time re-stocking and working on promotions instead of waiting for late shipments or dashing from store to store. FourKites’ solution also enables direct messaging with the driver, keeps a record of all past deliveries and provides ETAs for the next day’s shipments.

    “Our store managers use the FourKites Manager App,” said Adrian Santos, corporate director of transportation at Grocery Outlet. “It helps them manage labor better while giving the transport team more visibility in coordinating the final-mile deliveries.”
  • Recent enhancements to Appointment Manager make calendar blocks more flexible, helping stores better manage back-room operations and optimize labor to focus on sales and customer service.
  • Inbound shipment visibility: FourKites’ Network Visibility has been enhanced to allow retailers, vendors and carriers to see and collaborate on inbound pre-paid shipments to optimize staffing and manage capacity. More than 50,000 shipments are shared with retailers on a monthly basis.
  • FourKites is the only real-time visibility platform that offers multimodal SKU-level tracking, enabling customers to track shipments across their entire lifecycle using their associated PO number. FourKites co-innovated this solution together with major grocery retailer Meijer. The retailer ties real-time transportation visibility to purchase orders — not just loads — in order to optimize delivery of over 220,000 active SKUs to its 250+ stores.

    “Visibility has been hugely valuable for us, and as a large retailer and shipper, adding PO lifecycle visibility means we can identify critical orders faster, eliminate inefficiencies and make better decisions on lead times,” said Paul Thompson, Inbound Logistics Director, Meijer.
  • Instant Messenger: FourKites enhanced its instant messaging features to enable workers in track-and-trace and dispatch, drivers and warehouse personnel to share documents, photographs and notes for any given load.
  • Direct Store Delivery: New Direct Store Delivery tracking enables FourKites users to track last-mile shipments from local warehouses to retail outlets, giving retail workers immediate visibility into shipment ETA via their mobile devices.

To learn more about FourKites real-time visibility innovations for retailers, visit https://www.fourkites.com/industries/retail/.

About FourKites 
FourKites® is the #1 supply chain visibility platform in the world, extending visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 1 million shipments daily across road, rail, ocean, air, parcel and courier, and reaching 176 countries, FourKites combines real-time data and powerful machine learning to help companies digitize their end-to-end supply chains. More than 500 of the world’s most recognized brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains.

To learn more, visit https://www.fourkites.com/.

Media Contact: 
Marianna Vyridi 
Big Valley Marketing for FourKites 
(650) 468-3263 
[email protected]



Parsons Awarded $27 Million Contract By Georgia Department of Transportation To Improve I-285/I-20 East Interchange

CENTREVILLE, Va., May 19, 2021 (GLOBE NEWSWIRE) — Parsons Corporation (NYSE: PSN) announced today that the company was awarded a change order by the Georgia Department of Transportation (Georgia DOT) to continue serving as the owner’s representative and general engineering consultant for the I-285/I-20 East Interchange reconstruction. The $27 million contract includes concept development, environmental documentation, technical reviews and inspection services.

“Georgia DOT is working to deliver projects that will enhance the quality of life for its citizens by creating additional capacity on roads, improving freight movement, enhancing safety, and decreasing travel times and therefore carbon emissions,” said Mark Fialkowski, executive vice president, mobility solutions market for Parsons. “As we become more interconnected, we implement best practices to address environmental risk as part of our corporate ESG strategy. With more than 10,000 miles of road and highway projects completed around the world, our experts look forward to improving travel for Georgia drivers as we improve the I-285/I-20 East Interchange.”

The interchange reconstruction project is part of Georgia DOT’s Major Mobility Investment Program, which aims to reduce travel time, relieve traffic, curb pollution and improve safety throughout the state. Parsons has supported this program for four years as part of the I-285/I-20 East Interchange reconstruction general engineering services contract. This contract extension will allow Parsons to continue supporting the program through 2025 and aligns with our mission of delivering a better, more sustainable world.

To learn more about Parsons’ Road and Highway expertise, visit Parsons.com/road-highway/.


About Parsons

Parsons (NYSE: PSN) is a leading disruptive technology provider in the global defense, intelligence, and critical infrastructure markets, with capabilities across cybersecurity, missile defense, space, connected infrastructure, and smart cities. Please visit parsons.com and follow us on LinkedIn and Facebook to learn how we’re making an impact.

Media Contact:                                        
Theresa Wederman
+1 704.618.9710
[email protected]

Investor Relations Contact:
Dave Spille
+ 1 571.655.8264
[email protected]





Cytokinetics and The ALS Association Renew Partnership to Advance the Fight Against ALS

SOUTH SAN FRANCISCO, Calif. and WASHINGTON, May 19, 2021 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) and The ALS Association today announced the continuation of their partnership in the fight against ALS. Cytokinetics is a sponsor of the 2021 ALS Roundtables and ALS Focus, a patient and caregiver led survey program to learn about individual experiences with ALS. Cytokinetics is also a Platinum Level Sponsor for initiatives led by The ALS Association Golden West Chapter, including grant funding for care services for people with ALS in the Bay Area.

“We are proud to renew our enduring partnership and continue our support for The ALS Association and The ALS Association Golden West Chapter in the fight against ALS,” said Diane Weiser, Cytokinetics’ Senior Vice President of Corporate Communications & Investor Relations. “People with ALS are still desperately in need of new therapies as they continue to face daily challenges that are exacerbated by the pandemic. We hope to make a positive impact in the fight by potentially starting COURAGE-ALS, our Phase 3 trial of reldesemtiv in patients with ALS, later this year.”

In 2021, Cytokinetics will continue to support and participate in several virtual events and initiatives with The ALS Association focused on continuing disease awareness and education, including the 2021 ALS Roundtables, during which patients, caregivers, industry, researchers, insurers and clinicians convene to discuss various topics of importance to the ALS community.

As a supporter of initiatives led by The ALS Association Golden West Chapter for over 10 years, Cytokinetics has participated in local fundraising and awareness events, including the Napa Valley Ride to Defeat ALS and the Silicon Valley Walk to Defeat ALS. Despite the shift to virtual events, Cytokinetics is upholding its commitment to the local community through active participation.

“We are grateful to continue our longstanding partnership with Cytokinetics, a company that has consistently shown that their values and goals align with ours. Together we look forward to continuing to improve awareness, education, public policy, and access to care for those impacted by ALS,” said Lyles Eddins, Senior Vice President, Development and Field Operations of The ALS Association.

“We value Cytokinetics’ steadfast commitment to The ALS Golden West Chapter’s mission,” said Fred Fisher, MSW, LCSW, President and CEO of The ALS Association Golden West Chapter. “The ALS community has been impacted tremendously by the pandemic over the past year, and we are grateful for the continued support from partners like Cytokinetics. We are thrilled to continue working closely with them on events and strategic initiatives at the local level.”

About ALS

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that afflicts approximately 20,000 people in the United States and a comparable number of patients in Europe. Approximately 5,000 new cases of ALS are diagnosed each year in the United States. The average life expectancy of an ALS patient is approximately three to five years after diagnosis and only approximately 10 percent of patients survive for more than 10 years. Death is usually due to respiratory failure because of diminished strength in the skeletal muscles responsible for breathing. Few treatment options exist for these patients, resulting in a high unmet need for new therapies to address functional deficits and disease progression.

About The ALS Association

The ALS Association is the only national nonprofit organization fighting ALS on every front. By leading the way in global research, providing assistance for people with ALS through a nationwide network of chapters, coordinating multidisciplinary care through certified clinical care centers, and fostering government partnerships, the Association builds hope and enhances quality of life while aggressively searching for new treatments and a cure. For more information about The ALS Association, visit our website at www.alsa.org.

About the Golden West Chapter of The ALS Association

The Golden West Chapter of The ALS Association serves people with ALS and their families in 31 counties throughout California and in the state of Hawaii, with the goal of advancing the search for effective treatments and cures for ALS. The ALS Association Golden West Chapter is proud to have earned a Four-Star rating from Charity Navigator, America’s largest independent charity evaluator for eight consecutive years. This is the highest rating possible in recognition of the Chapter’s ongoing commitment to sound fiscal management, accountability and transparency. For more information about ALS and the Golden West Chapter, please visit www.alsagoldenwest.org and follow @alsagoldenwest on social media channels.

About Cytokinetics

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Cytokinetics is engaging with regulatory authorities in preparation for a U.S. NDA submission of omecamtiv mecarbil, its novel cardiac muscle activator, following positive results from GALACTIC-HF, a large, international Phase 3 clinical trial in patients with heart failure. Cytokinetics is conducting METEORIC-HF, a second Phase 3 clinical trial of omecamtiv mecarbil. Cytokinetics is also developing CK-274, a next-generation cardiac myosin inhibitor, for the potential treatment of hypertrophic cardiomyopathies (HCM). Cytokinetics is conducting REDWOOD-HCM, a Phase 2 clinical trial of CK-274 in patients with obstructive HCM. Cytokinetics is also developing reldesemtiv, a fast skeletal muscle troponin activator for the potential treatment of ALS and other neuromuscular indications following conduct of FORTITUDE-ALS and other Phase 2 clinical trials. The company is preparing for the potential advancement of reldesemtiv to a Phase 3 clinical trial in ALS. Cytokinetics continues its over 20-year history of pioneering innovation in muscle biology and related pharmacology focused to diseases of muscle dysfunction and conditions of muscle weakness.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on Twitter, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ and its partners’ research and development activities of Cytokinetics’ product candidates. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics’ business outlined in Cytokinetics’ filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics’ actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Communications, Investor Relations
(415) 290-7757



Qualigen Therapeutics, Inc. Appoints Tariq Arshad, MD, MBA as Chief Medical Officer

New Position Created
to
Deepen Clinical Expertise
and
Advance
Pipeline Therapeutic Programs

CARLSBAD, Calif., May 19, 2021 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, today announced the appointment of Tariq Arshad, MD, MBA to the newly-created position of Senior Vice President, Chief Medical Officer. Dr. Arshad brings more than 20 years of biotech and pharmaceutical experience to Qualigen Therapeutics during a dynamic time of growth and implementation of long-range strategy.

“We are delighted to welcome Tariq to Qualigen as our Chief Medical Officer during this exciting time where he will serve in a mission-critical role as we advance our oncology and viral disease pipeline programs,” stated Michael Poirier, Chairman and Chief Executive Officer at Qualigen Therapeutics.

Dr. Arshad is an oncologist with expertise in both early and late stage clinical development at several leading and emergent biopharmaceutical companies, including leadership roles at Becton Dickinson, Sanofi Genzyme, Humanigen, XOMA, Merck, Genentech, and Pfizer. Most recently, Dr. Arshad was Global Head of Medical Affairs and Clinical Research for Becton Dickinson BioSciences in San Jose, California where he led a team of MDs and PhDs driving scientific strategy for a cutting-edge immuno-oncology focused portfolio.

Dr. Arshad commented, “I am thrilled to join a dedicated team with a calling to develop therapeutics for patients with few treatment options. I plan to apply my expertise in immuno-oncology and clinical development to help solve the medical problems that devastate patients who suffer from these conditions.” 

About Qualigen Therapeutics, Inc.

Qualigen Therapeutics, Inc. is a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, as well as maintaining and expanding its core FDA-approved FastPack® System, which has been used successfully in diagnostics for 20 years. Our cancer therapeutics pipeline includes QN-247 (formerly referred to as ALAN or AS1411-GNP), RAS-F and STARS. QN-247 is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects; the nanoparticle coating technology is similar to the core nanoparticle coating technology used in our blood-testing diagnostic products. The foundational aptamer of QN-247, QN-165 (formerly referred to as AS1411), is also a drug candidate for treating COVID-19 and other viral-based infectious diseases; we currently plan that our first clinical trial would be a trial of QN-165 against COVID-19. RAS-F is a family of RAS oncogene protein-protein interaction inhibitor small molecules for preventing mutated RAS genes’ proteins from binding to their effector proteins; preventing this binding could stop tumor growth, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device candidate for removal from circulating blood of precisely targeted tumor-produced and viral compounds.

Because Qualigen’s therapeutic candidates are still in the development stage, Qualigen’s only products that are currently commercially available are FastPack System diagnostic instruments and test kits, used in physician offices, clinics and small hospitals around the world. The FastPack System menu includes rapid point-of-care diagnostic tests for cancer, men’s health, hormone function, and vitamin D status. Qualigen’s facility in Carlsbad, California is FDA and ISO Certified and its FastPack product line is sold worldwide by its commercial partner Sekisui Diagnostics, LLC.

For more information on Qualigen Therapeutics, Inc., please visit https://www.qualigeninc.com.

Forward-Looking Statements

This news release contains forward-looking statements by the Company that involve risks and uncertainties and reflect the Company’s judgment as of the date of this release. These statements include those related to the Company’s prospects and strategy for the development of therapeutic drug candidates. Actual events or results may differ from the Company’s expectations. For example, there can be no assurance that clinical trials will be approved to begin by or will proceed as contemplated by any projected timeline; that the Company will successfully develop any drugs or therapeutic devices; that preclinical or clinical development of the Company’s drugs or therapeutic devices will be successful; that future clinical trial data will be favorable or that such trials will confirm any improvements over other products or lack negative impacts; that any drugs or therapeutic devices will receive required regulatory approvals or that they will be commercially successful; that patents will issue on the Company’s owned and in-licensed patent applications; that such patents, if any, and the Company’s current owned and in-licensed patents would prevent competition; that the Company will be able to procure or earn sufficient working capital to complete the development, testing and launch of the Company’s prospective therapeutic products; or that the Company will be able to maintain or expand market demand and/or market share for the Company’s diagnostic products. The Company’s stock price could be harmed if any of the events or trends contemplated by the forward-looking statements fails to occur or is delayed or if any actual future event otherwise differs from expectations. Additional information concerning these and other risk factors affecting the Company’s business (including events beyond the Company’s control, such as epidemics and resulting changes) can be found in the Company’s prior filings with the Securities and Exchange Commission, available at www.sec.gov. The Company disclaims any intent or obligation to update these forward-looking statements beyond the date of this news release, except as required by law. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Investor Relations:

For further information: David Kugelman
Atlanta Capital Partners, LLC
(404) 856-9157 Office
(866) 692-6847 Toll Free – U.S. & Canada
[email protected]

Tony Schor
Investor Awareness, Inc.
(847) 971-0922
[email protected]

Attachment



Ebix Declares 7.5 Cent Quarterly Dividend, Payable June 15, 2021, to Shareholders of Record June 2, 2021

JOHNS CREEK, Ga., May 19, 2021 (GLOBE NEWSWIRE) — Ebix, Inc., (NASDAQ: EBIX) a leading international supplier of On-Demand software and E-commerce services to the insurance, financial, healthcare and e-learning industries, today announced that its Board of Directors has declared a regular quarterly dividend of 7.5 cents per common share. The dividend is payable June 15, 2021 to shareholders of record at the close of business on June 2, 2021.

About Ebix, Inc.

With 50+ offices across 6 continents, Ebix, Inc., (NASDAQ: EBIX) endeavors to provide On-Demand software and E-commerce services to the insurance, financial, healthcare and e-learning industries. In the Insurance sector, Ebix’s main focus is to develop and deploy a wide variety of insurance and reinsurance exchanges on an on-demand basis, while also, providing Software-as-a-Service (“SaaS”) enterprise solutions in the area of CRM, front-end & back-end systems, outsourced administration and risk compliance services, around the world.

With a “Phygital” strategy that combines 320,000 physical distribution outlets in many Southeast Asian Nations (“ASEAN”) countries, to an Omni-channel online digital platform, the Company’s EbixCash Financial exchange portfolio encompasses leadership in areas of domestic & international money remittance, foreign exchange (Forex), travel, pre-paid & gift cards, utility payments, lending, wealth management etc. in India and other markets. EbixCash’s Forex operations have emerged as a leader in India’s airport Foreign Exchange business with operations in 32 international airports including Delhi, Mumbai, Bangalore, Hyderabad, Chennai and Kolkata, conducting over $4.8 billion in gross transaction value per year. EbixCash’s inward remittance business in India conducts approx. $6.5 billion gross annual remittance business, confirming its undisputed leadership position in India. EbixCash, through its travel portfolio of Via and Mercury, is also one of Southeast Asia’s leading travel exchanges with over 2,200+ employees, 212,450+ agent network, 25 branches and over 9,800 corporate clients; processing an estimated $2.5 billion in gross merchandise value per year. For more information, visit the Company’s website at www.ebix.com.

CONTACT:

Darren Joseph or Gautam Sharma
678-281-2027 or [email protected]

David Collins or Chris Eddy
Catalyst Global – 212-924-9800 or [email protected]



Mydecine Provides Update on Spin-Out of U.S. Cannabis Assets

Spin-Out to Close On or About Week of July 12th

DENVER, May 19, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, today provided an update on its strategic reorganization (the “Spin-Out”) pursuant to which the Company intends to spin off its U.S. cannabis assets and its interests in U.S. cannabis projects1 into a newly incorporated subsidiary (“SpinCo”) in order to spin off its holdings of common shares in SpinCo to its existing shareholders. The Company expects to receive the interim order from the Supreme Court of British Columbia on or about June 7, 2021. Then, subject to approval of the shareholders, the Spin-Out is anticipated to close on or about the week of July 12, 2021.

The purpose of the Spin-Out will be, among other things, to permit the Company to comply with NASDAQ Listing Qualification requirements and comparable London Stock Exchange requirements regarding cannabis assets as the Company continues its listing review process with NASDAQ. Management believes that holding the U.S. cannabis assets and cannabis projects in a separate public company removes an unintended obstacle to its planned NASDAQ and London Stock Exchange listings and the expected benefits that such listings will provide the Company and its shareholders. Additionally, the Company plans to leverage and monetize the Company’s U.S. cannabis assets and cannabis projects and commercial relationships in the sector by spinning out the Company’s U.S. cannabis assets and cannabis projects into SpinCo.

It is proposed that the Spin-Out will be carried out by way of statutory plan of arrangement pursuant to the Business Corporations Act (British Columbia). Under the terms of the Spin-Out, shareholders of the Company will receive common shares of SpinCo on a pro rata basis based on the number of common shares of the Company held. The number of common shares of SpinCo to be issued to each shareholder of the Company under the Spin-Out has not yet been determined. There will be no change in shareholders’ holdings in the Company as a result of the Spin-Out.

The proposed Spin-Out will be subject to approval of shareholders of the Company, which the Company intends to seek at its next annual general and special meetings of shareholders (the “Shareholders’ Meeting”). The date for the Shareholders’ Meeting has not yet been determined. The Spin-Out also requires the approval of the British Columbia Supreme Court

Following the completion of the Spin-Out, SpinCo intends to make an application to list the SpinCo common shares on either the Canadian Securities Exchange or the NEO Exchange, but no assurance can be provided that such a listing will be obtained in a timely manner or at all. Any such listing will be subject to SpinCo fulfilling all the requirements of the applicable stock exchange.

Further details in respect of the Spin-Out, including the date for the Shareholders’ Meeting and the number of SpinCo common shares to be granted to shareholders of the Company will be announced in the near future. Readers are cautioned that the final details of the Spin-Out has yet to be determined and there is no certainty that the Spin-Out will be completed on the terms currently proposed or at all.

About Mydecine Innovations Group

Mydecine Innovations Group™ (NEO: MYCO) (OTC:MYCOF) (FSE:0NFA) is an emerging biotech and life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing vitality. The company’s world-renowned medical and scientific advisory board is building out a robust R&D pipeline of nature-sourced psychedelic-assisted therapeutics, novel compounds, therapy protocols, and unique delivery systems. Mydecine has exclusive access to a full cGMP certified pharmaceutical manufacturing facility with the ability to import/export, cultivate, extract/isolate, and analyze active mushroom compounds with full government approval through Health Canada. Mydecine also operates out of a state-of-the-art mycology lab in Denver, CO to focus on genetic research for scaling commercial cultivation of rare (non-psychedelic) medicinal mushrooms.

At the heart of Mydecine’s core philosophy is that psychedelic-assisted psychotherapy will continue to gain acceptance in the medical community with many of the world’s best accredited research organizations demonstrating its remarkable clinical effectiveness. Mydecine recognizes the responsibility associated with psychedelic-assisted therapy and will continue to position itself as a long-term leader across the spectrum of clinical trials, research, technology, and global supply. Mydecine has also successfully completed multiple acquisitions since its inception.

Learn more at: https://www.mydecine.com/ and follow us on FacebookTwitter, and Instagram.

For more information, please contact:

Media Contacts

Anne Donohoe / Nick Opich
KCSA Strategic Communications
[email protected]
1-212-896-1265 / 1-212-896-1206

Investor Contacts

Charles Lee, Investor Relations
[email protected]
1-720-277-9879

Allison Soss / Erika Kay
KCSA Strategic Communications
[email protected]
1-212-896-1267

On behalf of the Board of Directors:
Joshua Bartch, Chief Executive Officer
[email protected]

For further information about Mydecine Innovations Group, Inc., please visit the Company’s profile on SEDAR at www.sedar.com or visit the Company’s website at www.mydecine.com.

This news release contains forward-looking information within the meaning of Canadian securities laws regarding the Company and its business, which relate to future events or future performance and reflect management’s current expectations and assumptions. Often but not always, forward-looking information can be identified by the use of words such as “expect”, “intends”, “anticipated”, “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results “may”, “could”, “would” or “will” be taken, occur or be achieved. Forward-looking statements herein include, without limitation, statements relating to completion and timing of the Spin-Out, the listing of securities of the Company on NASDAQ or the London Stock Exchange, benefits of the Spin-Out for shareholders of the Company, the structure of the Spin-Out, SpinCo being able to leverage and monetize the Company’s U.S. cannabis assets and cannabis projects, the listing of the common shares of SpinCo on a stock exchange and the Company’s ability to build out a robust R&D pipeline. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward-looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, without limitation, risks regarding the ongoing COVID-19 pandemic, the availability and continuity of financing, the ability of the Company to adequately protect and enforce its intellectual property, the Company’s ability to bring its products to commercial production, continued growth of the global adaptive pathway medicine, natural health products and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale and use of the Company’s products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation.

1 Consider adding these references to the United States. Also we don’t use defined term “Cannabis Projects” in the rest of the press release.



Connected Car Data and New Telematics Technology Highlighted in IMS-Led Webinar

Executives from Zipcar, Audi, i247, and Athlon will share insights on implementation and business value from leading fleet industry solutions.

London, UK and Waterloo, Ontario, Canada, May 19, 2021 (GLOBE NEWSWIRE) — IMS (part of Trak Global Group), the leading global vehicle and driving data business, has announced the final speaker line-up for its upcoming webinar, “Global Case Study: How to Extract Value from Connected Car Data and Telematics Technology,” which will be held on June 15 at 9:00am EST/3:00pm CET time. 

Moderated by Leon Hurst, CEO Mobility for IMS, this webinar will explore how leading fleet-based organizations are embracing new developments in connected car data, telematics technology, and data exchange platforms to rapidly shift from reactive to proactive operations. The panel will include IMS customers James Taylor, General Manager for Zipcar, Thomas Bayerl, Digital Business Development for Audi Germany, Stephen Thornton, Commercial Director for i247, and Martin Philips, Chief Operating Officer for Athlon, as well as Matthew Waller, Director of Mobility Solutions for IMS. 

“While fleet and mobility leaders are beginning to embrace telematics technology to get rich vehicle insights directly from connected car data and OEM sources, new and powerful case studies are emerging which highlight the benefits of true live connectivity across an entire fleet,” said Hurst. “This webinar explores how businesses across a variety of different vehicle segments are adopting connected data to broaden their customer propositions as well as transforming their operations and total cost of ownership.”

During this webinar, attendees will hear specific case studies across the mobility value chain including car clubs/car sharing, leasing, vehicle rental, service, maintenance, and repair (SMR), and original equipment manufacturer (OEM) professionals which demonstrate ways of improving business operations and digitally transforming manual processes, lowering costs, and offering better service to the end customer. The primary discussion will center around the business value and benefits of live connectivity and connected car data, including best practices for using direct OEM-embedded technology, in addition to exploring what the future holds for this technology for the forward-thinking companies adopting it today.

Register for this webinar today at https://hopin.com/events/fleet-europe-webinar-with-ims

# # #

About IMS (Insurance & Mobility Solutions)

IMS (Insurance & Mobility Solutions) is a vehicle and driving data business, delivering enterprise solutions to over 350 customers including insurers, mobility operators and governments. IMS recently launched its Vehicle Data Exchange, which enables the IMS DriveSync platform to ingest and process data from any source – from OEM embedded units to smartphones and aftermarket hardware. The company, with offices in the UK, Europe and N. America, has analysed over 15 billion driving miles and its algorithms are fed by trillions of data points every hour. More info at https://www.ims.tech

Attachments



Jennifer Overhulse
St. Nick Media Services
859-803-6597
[email protected]

Endava Announces Third Quarter Fiscal Year 2021 Results

Endava Announces Third Quarter Fiscal Year 2021 Results

Q3 FY2021

21.8% Year on Year Revenue Growth to £112.3 million

23.8% Revenue Growth at Constant Currency

IFRS diluted EPS £0.23 compared to £0.26 in the prior year comparative period

Adjusted diluted EPS £0.34 compared to £0.23 in the prior year comparative period

LONDON–(BUSINESS WIRE)–
Endava plc(NYSE: DAVA) (“Endava” or the “Company”) a global provider of digital transformation, agile development and intelligent automation services, today announced results for the three months ended March 31, 2021, the third quarter of its 2021 fiscal year (“Q3 FY2021”).

“Endava delivered another outstanding quarter with revenue for Q3 FY2021 of £112.3 million, an increase of 21.8% Year on Year. Demand for digital transformation services continues to grow in all regions and verticals,” said John Cotterell, Endava’s CEO.

THIRD QUARTER FISCAL YEAR 2021 FINANCIAL HIGHLIGHTS:

  • Revenue for Q3 FY2021 was £112.3 million, an increase of 21.8% compared to £92.2 million in the same period in the prior year.
  • Revenue growth rate at constant currency(a non-IFRS measure) was 23.8% for Q3 FY2021 compared to 25.7% in the same period in the prior year.
  • Profit before tax for Q3 FY2021 was £16.5 million compared to £18.3 million in the same period in the prior year.
  • Adjusted profit before tax (a non-IFRS measure) for Q3 FY2021 was £23.9 million, compared to £16.0 million in the same period in the prior year, or 21.3% of revenue, compared to 17.4% of revenue in the same period in the prior year.
  • Profit for the period was £13.0 million in Q3 FY2021, resulting in a diluted EPS of £0.23, compared to profit of £14.6 million and diluted EPS of £0.26 in the same period in the prior year.
  • Adjusted profit for the period (a non-IFRS measure) was £19.3 million in Q3 FY2021, resulting in adjusted diluted EPS (a non-IFRS measure) of £0.34 compared to adjusted profit for the period of £12.8 million and adjusted diluted EPS of £0.23 in the same period in the prior year.

CASH FLOW:

  • Net cash from operating activities was £11.6 million in Q3 FY2021 compared to £11.8 million in the same period in the prior year.
  • Adjusted free cash flow (a non-IFRS measure) was £10.2 million in Q3 FY2021 compared to £9.6 million in the same period in the prior year.
  • At March 31, 2021, Endava had cash and cash equivalents of £78.8 million, compared to £101.3 million at June 30, 2020.

OTHER METRICS FOR THE QUARTER ENDED MARCH 31, 2021:

  • Headcount reached 8,127 at March 31, 2021, with 7,068 average operational employees in Q3 FY2021, compared to a headcount of 6,468 at March 31, 2020 and 5,787 average operational employees in the same quarter of the prior year.
  • Number of clients with over £1 million in revenue on a rolling twelve months basis was 81 at March 31, 2021, compared to 67 at March 31, 2020.
  • Top 10 clients accounted for 36% of revenue in Q3 FY2021, unchanged compared to March 31, 2020.
  • By geographic region, 29% of revenue was generated in North America, 25% was generated in Europe, 43% was generated in the United Kingdom and 3% was generated in the rest of the world in Q3 FY2021. This compares to 27% in North America, 25% in Europe, 45% in the United Kingdom and 3% in the rest of the world in the same period in the prior year.
  • By industry vertical, 53% of revenue was generated from Payments and Financial Services, 27% from TMT and 20% from Other. This compares to 54% from Payments and Financial Services, 25% from TMT and 21% from Other in the same period in the prior year. 

BUSINESS HIGHLIGHTS:

  • On March 4, 2021, Endava announced the acquisition of Pet Minuta d.o.o. of Croatia and its U.S. subsidiary, Five Minutes Studio, Inc. (together “FIVE”). FIVE, based in Brooklyn, NY and Croatia, is a digital agency delivering a full spectrum of services, including product strategy, the design, build and delivery of digital experiences, and ongoing growth marketing using agile methodology combined with a scientific/metrics-driven approach to product design. FIVE had a team of 157 operational employees as of the date of acquisition, based in Brooklyn, NY and Croatia. The majority of its people are based in delivery centers in Croatia’s four largest cities.
  • On April 1, 2021, Endava announced the acquisition of Levvel LLC, headquartered in Charlotte, NC (“Levvel”). Levvel is an award-winning U.S. technology strategy, consulting and engineering firm focused on helping companies create sophisticated technology through human-centered problem solving, rooted in deep industry expertise. Levvel has a strong focus in the Payments and Financial Services, Logistics/Mobility and TMT segments, and Endava expects the acquisition to enable it to continue to expand in the United States while serving clients in these core market sectors. Levvel delivers from the United States and Mexico and had 172 operational employees as of the date of acquisition, many of whom hold certifications, and maintains partnerships with key cloud platforms and leading and emerging technologies. 

OUTLOOK:

At this time, the general economic environment remains fluid and it continues to be challenging to anticipate the ultimate full scope and duration of the impact of the COVID-19 pandemic. Endava is providing guidance for the fourth quarter of its 2021 fiscal year and its full 2021 fiscal year based upon what it currently sees in its markets.

Fourth Quarter Fiscal Year 2021:

Endava expects revenues will be in the range £130.0 million to £132.0 million, representing constant currency revenue growth of between 51.0% and 53.0%. Endava expects adjusted diluted EPS to be in the range of £0.34 to £0.36 per share.

Full Fiscal Year 2021:

Endava expects revenues will be in the range £443.0 million to £445.0 million, representing constant currency growth of between 29.0% and 30.0%. Endava expects adjusted diluted EPS to be in the range of £1.22 to £1.24 per share.

The constant currency growth figure now quoted for the full fiscal year 2021 guidance still includes the proforma adjustment for the Worldpay Captive, which Endava sold in August 2019, as it remains in the full year comparative.

This above guidance for Q4 Fiscal Year 2021 and the Full Fiscal Year 2021 assumes the exchange rates at the end of April (when the exchange rate was 1 British Pound to 1.39 US Dollar and 1.15 Euro).

Endava is not able, at this time, to provide an outlook for IFRS diluted EPS for Q4 FY2021 or FY2021 because of the unreasonable effort of estimating on a forward-looking basis certain items that are excluded from adjusted diluted EPS, including, for example, share-based compensation expense, amortisation of acquired intangible assets and foreign currency exchange (gains)/losses, the effect of which may be significant. Endava is also not able, at this time, to reconcile to an outlook for revenue growth not at constant currency because of the unreasonable effort of estimating foreign currency exchange gains/losses, the effect of which may be significant, on a forward-looking basis.

The guidance provided above is forward-looking in nature. Actual results may differ materially. See the cautionary note regarding “Forward-Looking Statements” below.

CONFERENCE CALL DETAILS:

The Company will host a conference call at 8:00 am EDT today, May 19, 2021, to review its Q3 FY2021 results. To participate in Endava’s Q3 FY2021 earnings conference call, please dial in at least five minutes prior to the scheduled start time (833) 921-1651 or (778) 560-2811 for international participants, Conference ID 1517596.

Investors may listen to the call on Endava’s Investor Relations website at http://investors.Endava.com. The webcast will be recorded and available for replay until Friday, June 4, 2021.

ABOUT ENDAVA PLC:

Endava is a leading next-generation technology services provider and helps accelerate disruption by delivering rapid evolution to enterprises. Using distributed enterprise agile at scale, Endava collaborates with its clients, seamlessly integrating with their teams, catalysing ideation and delivering robust solutions. Endava helps its clients become digital, experience-driven businesses by assisting them in their journey from idea generation to development and deployment of products, platforms and solutions. It services clients in the following industries: Payments and Financial Services, TMT and “Other,” which includes Consumer Products, Retail, Mobility and Healthcare. Endava had 8,127 employees (including directors) as of March 31, 2021 located in North America, Western Europe, Australia and Singapore and delivery centres in Romania, Moldova, Bulgaria, Serbia, Croatia, North Macedonia, Slovenia, Bosnia & Herzegovina, Argentina, Uruguay, Venezuela, and Colombia.

NON-IFRS FINANCIAL INFORMATION:

To supplement Endava’s Consolidated Statements of Comprehensive Income, Consolidated Balance Sheets and Consolidated Statements of Cash Flow presented in accordance with IFRS, the Company uses non-IFRS measures of certain components of financial performance. These measures include: revenue growth rate at constant currency, revenue growth at constant currency adjusted for the sale of Endava Technology SRL, also referred to as “the Worldpay Captive” to Worldpay on August 31, 2019, adjusted profit before tax, adjusted profit for the period, adjusted diluted EPS and adjusted free cash flow.

Revenue growth rate at constant currency is calculated by translating revenue from entities reporting in foreign currencies into British Pounds using the comparable foreign currency exchange rates from the prior period. For example, the average rates in effect for the fiscal quarter ended March 31, 2020 were used to convert revenue for the fiscal quarter ended March 31, 2021 and the revenue for the comparable prior period.

Revenue growth at constant currency adjusted for the sale of the Worldpay Captive is revenue growth at constant currency adjusted to exclude the impact of the sale of the Worldpay Captive.

Adjusted profit before tax (“Adjusted PBT”) is defined as the Company’s profit before tax adjusted to exclude the impact of share-based compensation expense, discretionary EBT bonus, amortisation of acquired intangible assets, realised and unrealised foreign currency exchange gains and losses, and net gain on disposal of subsidiary. Share-based compensation expense, amortisation of acquired intangible assets and unrealized foreign currency gains are non-cash expenses. Adjusted PBT margin is Adjusted PBT as a percentage of total revenue.

Adjusted profit for the period is defined as Adjusted PBT together with the tax impact of these adjustments.

Adjusted diluted EPS is defined as Adjusted profit for the period, divided by weighted average number of shares outstanding – diluted.

Adjusted free cash flow is the Company’s net cash from operating activities, plus grants received, less net purchases of non-current assets (tangible and intangible).

Management believes these measures help illustrate underlying trends in the Company’s business and uses the measures to establish budgets and operational goals, communicated internally and externally, for managing the Company’s business and evaluating its performance. Management also believes the presentation of its non-IFRS financial measures enhances an investor’s overall understanding of the Company’s historical financial performance. The presentation of the Company’s non-IFRS financial measures is not meant to be considered in isolation or as a substitute for the Company’s financial results prepared in accordance with IFRS, and its non-IFRS measures may be different from non-IFRS measures used by other companies. Investors should review the reconciliation of the Company’s non-IFRS financial measures to the comparable IFRS financial measures included below, and not rely on any single financial measure to evaluate the Company’s business.

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by the use of terms and phrases such as “believe,” “expect,” “outlook,” “may,” “will”, and other similar terms and phrases. Such forward-looking statements include, but are not limited to, the statements regarding Endava’s projected financial performance for the fourth fiscal quarter of fiscal year 2021 and the full fiscal year 2021, the challenges presented by the ongoing COVID-19 pandemic and the associated global economic uncertainty, and anticipated benefits from recent acquisitions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated by these forward-looking statements, including, but not limited to: Endava’s business, results of operations and financial condition may be negatively impacted by the COVID-19 pandemic and the precautions taken in response to the pandemic or if general economic conditions in Europe, the United States or the global economy worsen; Endava’s ability to manage its rapid growth or achieve anticipated growth; Endava’s ability to retain existing clients and attract new clients, including its ability to increase revenue from existing clients and diversify its revenue concentration; Endava’s ability to attract and retain highly-skilled IT professionals at cost-effective rates; Endava’s ability to penetrate new industry verticals and geographies and grow its revenue in current industry verticals and geographies; Endava’s ability to maintain favourable pricing and utilisation rates; Endava’s ability to successfully identify acquisition targets, consummate acquisitions and successfully integrate acquired businesses and personnel; the effects of increased competition as well as innovations by new and existing competitors in its market; Endava’s ability to adapt to technological change and innovate solutions for its clients; Endava’s ability to collect on billed and unbilled receivables from clients; Endava’s ability to effectively manage its international operations, including Endava’s exposure to foreign currency exchange rate fluctuations; Endava’s ability to remediate the identified material weaknesses and maintain an effective system of disclosure controls and internal control over financial reporting, and Endava’s future financial performance, including trends in revenue, cost of sales, gross profit, selling, general and administrative expenses, finance income and expense and taxes, as well as other risks and uncertainties discussed in the “Risk Factors” section of our Annual Report on Form 20-F filed with the Securities and Exchange Commission (“SEC”) on September 15, 2020. In addition, the forward-looking statements included in this press release represent Endava’s views and expectations as of the date hereof and are based on information currently available to Endava. Endava anticipates that subsequent events and developments may cause its views to change. Endava specifically disclaims any obligation to update the forward-looking statements in this press release except as required by law. These forward-looking statements should not be relied upon as representing Endava’s views as of any date subsequent to the date hereof.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

 

Nine Months Ended

March 31

Three Months Ended

March 31

 

2021

2020

2021

2020

 

£’000

£’000

£’000

£’000

REVENUE

312,676

 

260,487

 

112,311

 

92,235

 

Cost of sales

 

 

 

 

Direct cost of sales

(189,655

)

(174,481

)

(69,176

)

(51,889

)

Allocated cost of sales

(14,533

)

(12,902

)

(4,621

)

(4,591

)

Total cost of sales

(204,188

)

(187,383

)

(73,797

)

(56,480

)

GROSS PROFIT

108,488

 

73,104

 

38,514

 

35,755

 

Selling, general and administrative expenses

(64,737

)

(58,094

)

(20,476

)

(21,614

)

OPERATING PROFIT

43,751

 

15,010

 

18,038

 

14,141

 

Net finance (expense) / income

(7,921

)

1,282

 

(1,541

)

4,153

 

Gain on sale of subsidiary

 

2,215

 

 

 

PROFIT BEFORE TAX

35,830

 

18,507

 

16,497

 

18,294

 

Tax on profit on ordinary activities

(8,337

)

(3,206

)

(3,511

)

(3,689

)

PROFIT FOR THE PERIOD

27,493

 

15,301

 

12,986

 

14,605

 

OTHER COMPREHENSIVE INCOME

 

 

 

 

Items that may be reclassified subsequently to profit or loss:

 

 

 

 

Exchange differences on translating foreign operations

(9,512

)

(3,598

)

(6,021

)

787

 

TOTAL COMPREHENSIVE INCOME FOR THE PERIOD ATTRIBUTABLE TO OWNERS OF THE PARENT

17,981

 

11,703

 

6,965

 

15,392

 

 

 

 

 

 

EARNINGS PER SHARE (EPS):

 

 

 

 

Weighted average number of shares outstanding – Basic

55,081,386

 

53,170,717

 

55,581,888

 

53,815,137

 

Weighted average number of shares outstanding – Diluted

56,749,298

 

55,832,497

 

57,203,008

 

56,345,433

 

Basic EPS (£)

0.50

 

0.29

 

0.23

 

0.27

 

Diluted EPS (£)

0.48

 

0.27

 

0.23

 

0.26

 

 

CONDENSED CONSOLIDATED BALANCE SHEETS

 

March 31, 2021

June 30, 2020

March 31, 2020

 

£’000

£’000

£’000

(Restated) (1)

ASSETS – NON-CURRENT

 

 

 

Goodwill

119,506

56,885

56,219

Intangible assets

32,870

38,751

39,507

Property, plant and equipment

11,590

12,747

11,877

Lease right-of-use assets

41,927

51,134

48,634

Financial assets

529

639

850

Deferred tax assets

12,970

13,340

9,331

TOTAL

219,392

173,496

166,418

ASSETS – CURRENT

 

 

 

Trade and other receivables

109,104

82,614

76,496

Corporation tax receivable

1,463

2,922

5,152

Financial assets

559

584

595

Cash and cash equivalents

78,836

101,327

87,159

TOTAL

189,962

187,447

169,402

TOTAL ASSETS

409,354

360,943

335,820

LIABILITIES – CURRENT

 

 

 

Lease liabilities

12,170

11,132

10,763

Trade and other payables

65,379

58,599

63,241

Corporation tax payable

3,524

1,449

4,255

Contingent consideration

1,082

1,442

1,203

Deferred consideration

2,693

3,764

1,787

TOTAL

84,848

76,386

81,249

LIABILITIES – NON CURRENT

 

 

 

Lease liabilities

34,561

42,233

40,409

Deferred tax liabilities

5,149

5,861

5,000

Contingent consideration

1,794

Deferred consideration

7,501

1,919

Other liabilities

153

136

121

TOTAL

49,158

48,230

47,449

EQUITY

 

 

 

Share capital

1,114

1,099

1,098

Share premium

230

221

189

Merger relief reserve

30,003

25,527

25,527

Retained earnings

257,485

214,638

172,262

Other reserves

(13,329)

(3,817)

9,487

Investment in own shares

(155)

(1,341)

(1,441)

TOTAL

275,348

236,327

207,122

TOTAL LIABILITIES AND EQUITY

409,354

360,943

335,820

1) The restatement refers to a reclassification of £21,097,000 from share premium to merger relief reserve.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

 

Nine Months Ended

March 31

Three Months Ended

March 31

 

2021

2020

2021

2020

 

£’000

£’000

£’000

£’000

OPERATING ACTIVITIES

 

 

 

 

Profit for the period

27,493

15,301

12,986

14,605

Income tax charge

8,337

3,206

3,511

3,689

Non-cash adjustments

39,088

20,062

11,602

4,176

Tax paid

(788)

(4,446)

(140)

(911)

UK research and development credit received

2,930

1,619

Net changes in working capital

(23,626)

4,223

(18,027)

(9,713)

Net cash from operating activities

53,434

38,346

11,551

11,846

 

 

 

 

 

INVESTING ACTIVITIES

 

 

 

 

Purchase of non-current assets (tangibles and intangibles)

(3,752)

(8,075)

(1,408)

(2,245)

Proceeds from disposal of non-current assets

150

150

42

30

Acquisition of business / subsidiaries, consideration in cash

(65,942)

(26,595)

(13,810)

466

Proceeds from sale of subsidiary net of cash disposed of

2,744

Cash and cash equivalents acquired with subsidiaries

2,722

3,289

1,119

Interest received

76

477

23

124

Net cash used in investing activities

(66,746)

(28,010)

(14,034)

(1,625)

 

 

 

 

 

FINANCING ACTIVITIES

 

 

 

 

Proceeds from sublease

424

406

135

104

Repayment of borrowings

(955)

(946)

Repayment of lease liabilities

(8,442)

(7,157)

(2,696)

(2,588)

Interest paid

(674)

(603)

(230)

(228)

Grant received

267

661

47

Proceeds from sale of EBT shares

14,797

Issue of shares

9

61

52

Net cash from financing activities

(8,416)

7,210

(2,744)

(3,606)

Net change in cash and cash equivalents

(21,728)

17,546

(5,227)

6,615

 

 

 

 

 

Cash and cash equivalents at the beginning of the period

101,327

70,172

84,221

78,975

Exchange differences on cash and cash equivalents

(763)

(559)

(158)

1,569

Cash and cash equivalents at the end of the period

78,836

87,159

78,836

87,159

RECONCILIATION OF IFRS FINANCIAL MEASURES TO NON-IFRS FINANCIAL MEASURES

RECONCILIATION OF REVENUE GROWTH RATE AS REPORTED UNDER IFRS TO REVENUE GROWTH RATE AT CONSTANT CURRENCY:

 

 

Nine Months ended

March 31

Three Months ended

March 31

 

2021

2020

2021

2020

REVENUE GROWTH RATE AS REPORTED UNDER IFRS

20.0 %

23.3 %

21.8 %

26.2 %

Foreign exchange rates impact

0.9 %

(0.7 %)

2.0 %

(0.5 %)

REVENUE GROWTH RATE AT CONSTANT CURRENCY INCLUDING WORLDPAY CAPTIVE 

20.9 %

22.6 %

23.8 %

25.7 %

Impact of Worldpay Captive

1.0 %

3.0 %

4.3 %

PRO-FORMA REVENUE GROWTH RATE AT CONSTANT CURRENCY ADJUSTED FOR THE SALE OF THE WORLDPAY CAPTIVE

21.9 %

25.6 %

23.8 %

30.0 %

RECONCILIATION OF ADJUSTED PROFIT BEFORE TAX AND ADJUSTED PROFIT FOR THE PERIOD:

 

 

Nine Months Ended

March 31

Three Months Ended

March 31

 

2021

2020

2021

2020

 

£’000

£’000

£’000

£’000

 

 

 

 

 

PROFIT BEFORE TAX

35,830

18,507

16,497

18,294

Adjustments:

 

 

 

 

Share-based compensation expense

17,518

11,075

5,622

4,079

Discretionary EBT bonus

24,766

(2,891)

Amortisation of acquired intangible assets

3,345

2,933

1,065

1,124

Foreign currency exchange losses / (gains), net

6,031

(1,664)

727

(4,577)

Net gain on disposal of subsidiary

(2,215)

Total adjustments

26,894

34,895

7,414

(2,265)

ADJUSTED PROFIT BEFORE TAX

62,724

53,402

23,911

16,029

 

 

 

 

 

PROFIT FOR THE PERIOD

27,493

15,301

12,986

14,605

Adjustments:

 

 

 

 

Adjustments to profit before tax

26,894

34,895

7,414

(2,265)

Tax impact of adjustments

(4,083)

(7,073)

(1,117)

435

ADJUSTED PROFIT FOR THE PERIOD

50,304

43,123

19,283

12,775

 

 

 

 

 

Diluted EPS (£)

0.48

0.27

0.23

0.26

Adjusted diluted EPS (£)

0.89

0.77

0.34

0.23

RECONCILIATION OF NET CASH FROM OPERATING ACTIVITIES TO ADJUSTED FREE CASH FLOW

 

 

Nine Months Ended

March 31

Three Months Ended

March 31

 

2021

2020

2021

2020

 

£’000

£’000

£’000

£’000

 

 

 

 

 

Net cash from operating activities

53,434

38,346

11,551

11,846

Adjustments:

 

 

 

 

Grant received

267

661

47

Purchases of non-current assets (tangibles and intangibles)

(3,602)

(7,925)

(1,366)

(2,215)

Adjusted Free cash flow

50,099

31,082

10,232

9,631

SUPPLEMENTARY INFORMATION

SHARE-BASED COMPENSATION EXPENSE

 

 

Nine Months

Ended

March 31

Three Months

Ended

March 31

 

2021

2020

2021

2020

 

£’000

£’000

£’000

£’000

 

 

 

 

 

Direct cost of sales

10,513

6,148

3,449

2,318

Selling, general and administrative expenses

7,005

4,927

2,173

1,761

Total

17,518

11,075

5,622

4,079

DEPRECIATION AND AMORTISATION

 

 

Nine Months Ended

March 31

Three Months Ended

March 31

 

2021

2020

2021

2020

 

£’000

£’000

£’000

£’000

 

 

 

 

 

Direct cost of sales

11,341

9,153

3,478

3,243

Selling, general and administrative expenses

5,147

4,473

1,579

1,639

Total

16,488

13,626

5,057

4,882

EMPLOYEE BENEFIT TRUST DISCRETIONARY BONUS

 

 

Nine Months Ended

March 31

Three Months Ended

March 31

 

2021

2020

2021

2020

 

£’000

£’000

£’000

£’000

 

 

 

 

 

Direct cost of sales

22,555

(2,627)

Selling, general and administrative expenses

2,211

(264)

Total

24,766

(2,891)

EMPLOYEES, TOP 10 CUSTOMERS AND REVENUE SPLIT

 

 

Nine Months Ended

March 31

Three Months Ended

March 31

 

2021

2020

2021

2020

 

 

 

 

 

Closing number of total employees (including directors)

8,127

6,468

8,127

6,468

Average operational employees

6,634

5,532

7,068

5,787

 

 

 

 

 

Top 10 customers %

37%

38%

36%

36%

Number of clients with > £1m of revenue

(rolling 12 months)

81

67

81

67

 

 

 

 

 

Geographic split of revenue %

 

 

 

 

North America

29%

28%

29%

27%

Europe

26%

24%

25%

25%

UK

42%

45%

43%

45%

Rest of World (RoW)

3%

3%

3%

3%

Industry vertical split of revenue %

 

 

 

 

Payments and Financial Services

50%

53%

53%

54%

TMT

28%

25%

27%

25%

Other

22%

22%

20%

21%

 

INVESTOR CONTACT:

Endava Plc

Laurence Madsen, Investor Relations Manager

[email protected]

KEYWORDS: Europe United States United Kingdom North America

INDUSTRY KEYWORDS: Professional Services Technology Other Professional Services Other Technology Software Consulting

MEDIA:

Sokoman Announces Results of Extraordinary General Meeting of Shareholders

Sokoman Announces Results of Extraordinary General Meeting of Shareholders

ST. JOHN’S, Newfoundland and Labrador–(BUSINESS WIRE)–
Sokoman Minerals Corp. (TSX.V: SIC) (OTCQB: SICNF) (the “Company” or “Sokoman”) today announced that at the Company’s Extraordinary General Meeting of Shareholders held on Tuesday, May 18th, the Company received shareholder approval for Mr. Eric Sprott to become a greater than 20% shareholder of Sokoman.

About Sokoman Minerals Corp.

Sokoman Minerals Corp. is a discovery-oriented company with projects in Newfoundland & Labrador, Canada. The Company’s primary focus is its portfolio of gold projects Moosehead, Crippleback Lake and East Alder (optioned to Canterra Minerals Corporation) along the Central Newfoundland Gold Belt, and the recently acquired district-scale Fleur de Lys project in northwestern Newfoundland, which is targeting Dalradian-type orogenic gold mineralization similar to the Curraghinalt and Cavanacaw deposits in Northern Ireland. Sokoman controls one of the largest land holdings in Newfoundland with over 50,000 hectares (250 km2) of highly prospective ground in Canada’s newest and rapidly emerging gold districts. The Company also retains an interest in an early-stage antimony/gold project (Startrek) in Newfoundland, optioned to White Metal Resources Inc., and in Labrador, the Company has a 100% interest in the Iron Horse (Fe) project that has Direct Shipping Ore (DSO) potential.

Mineralization hosted on adjacent and/or nearby properties is not necessarily indicative of mineralization hosted on the Company’s property.

The Company would like to thank the Government of Newfoundland and Labrador for financial support of the Moosehead Project through the Junior Exploration Assistance Program.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Investors are cautioned that trading in the securities of the Corporation should be considered highly speculative. Except for historical information contained herein, this news release contains forward- looking statements that involve risks and uncertainties. Actual results may differ materially. Sokoman Minerals Corp. will not update these forward-looking statements to reflect events or circumstances after the date hereof. More detailed information about potential factors that could affect financial results is included in the documents filed from time to time with the Canadian securities regulatory authorities by Sokoman Minerals Corp.

To learn more:

Timothy Froude, P. Geo., President & CEO

709-765-1726

[email protected]

Cathy Hume, Director, Investor Relations

416-868-1079 x251

[email protected]

Website:www.sokomanmineralscorp.com

Twitter: @SokomanMinerals

Facebook: @SokomanMinerals

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Mining/Minerals Natural Resources

MEDIA: